<code id='39FEADA79D'></code><style id='39FEADA79D'></style>
    • <acronym id='39FEADA79D'></acronym>
      <center id='39FEADA79D'><center id='39FEADA79D'><tfoot id='39FEADA79D'></tfoot></center><abbr id='39FEADA79D'><dir id='39FEADA79D'><tfoot id='39FEADA79D'></tfoot><noframes id='39FEADA79D'>

    • <optgroup id='39FEADA79D'><strike id='39FEADA79D'><sup id='39FEADA79D'></sup></strike><code id='39FEADA79D'></code></optgroup>
        1. <b id='39FEADA79D'><label id='39FEADA79D'><select id='39FEADA79D'><dt id='39FEADA79D'><span id='39FEADA79D'></span></dt></select></label></b><u id='39FEADA79D'></u>
          <i id='39FEADA79D'><strike id='39FEADA79D'><tt id='39FEADA79D'><pre id='39FEADA79D'></pre></tt></strike></i>

          knowledge

          knowledge

          author:Wikipedia    Page View:2243
          Adobe

          Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI, they say.

          In a small study published Wednesday — just 10 people with severe, treatment-resistant depression receiving deep brain stimulation therapy — researchers used the electrodes to record brain activity and later fed the scans into a homegrown artificial intelligence system that analyzed them for patterns. They found that it was possible to track patients’ recovery through changes in brain cells’ electrical activity.

          advertisement

          Finding so-called biomarkers, or objective measurements reflecting depression, could help diagnose depression, track its progression, predict a relapse, and better tailor therapies to individual patients. But finding those metrics has been difficult, partly because depression’s biological impact isn’t well understood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          H.R. 3 is the wrong path to lower drug costs
          H.R. 3 is the wrong path to lower drug costs

          Fromleft,Rep.RichardNeal(D-Mass.)speaksasRep.FrankPallone(D-N.J.)andHouseSpeakerNancyPelosi(D-Calif.

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          When a patient nears the end, a feared therapy can comfort

          ArmellaLeungforSTATItwasmid-October2008whenthemedicsrolledtheelderlymanthroughtheglass-enclosedlobby